Eli Lilly reported positive top‑line Phase III results for retatrutide (a GIP/GLP‑1/glucagon triple agonist) in patients with type‑2 diabetes, showing marked A1C reductions and substantial weight loss at 40 weeks. The Transcend‑T2D‑1 trial met its primary endpoint for glycemic control and key secondary endpoints for weight, with the highest dose delivering up to a 1.9 percentage‑point A1C drop and mean weight loss comparable to leading anti‑obesity agents. Lilly said safety and discontinuation rates were consistent with the GLP‑1 class; common adverse events included gastrointestinal effects. The data expand retatrutide’s positioning across diabetes and obesity and set the stage for regulatory filings and commercial planning.